IonQ acquires majority stake in id Quantique
IonQ has entered into a definitive agreement with SK Telecom and id Quantique to acquire a controlling interest in id Quantique in a share-for-share transaction.
BioVersys completes its IPO at SIX Swiss Exchange
BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, has completed its Initial Public at the SIX Swiss Exchange.
ATANIS Biotech completes Financing Round
ATANIS Biotech, a Swiss biotechnology company specializing in advanced allergy diagnostics, has successfully completed an oversubscribed financing round led by Spectrum Moonshot Fund and supported by experienced investors in the allergy field.
VISCHER advises Kelun-Biotech, Harbour BioMed and RTW Investments in USD 200m Series A Financing of Windward Bio
Windward Bio Group AG, a Basel-based private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases, announced its launch with a USD 200m series A financing from lead investors OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities, and co-investors SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital and Pivotal bioVenture Partners.
Avenir Group enters into strategic partnership with Liberta Partners
Avenir Group, a leading company in the development and implementation of integrated services and solutions in human resource management, enters into a strategic partnership with Liberta Partners, a Munich-based multi-family office.
Ikerian closes Series B Financing with strategic partnership
Ikerian, a healthcare software platform company that organizes multimodal data at-scale, closes the first tranche of USD 8m Series B Financing to advance its AI platform alongside.
MegaCAD aquires Bausoft Informatik AG
MegaCAD GmbH acquires Bausoft Informatik AG, a leading Swiss software manufacturer for building engineering services.
ImmunOs Therapeutics AG closes Series C financing round
ImmunOs Therapeutics AG, in Schlieren, a biopharmaceutical company developing first-in-class therapeutics for the treatment of cancer and autoimmune diseases based on its unique immune system modulating technology platform, closed a Series C financing round.
Santis Pharma receives investment from Abenex
The founders of Santis Pharma, a Franco-Swiss laboratory company developing and marketing food supplements with health benefits, have entered into a partnership with Abenex, a French private equity investor.
HAYA Therapeutics Announces Collaboration with Eli Lilly
HAYA Therapeutics SA, a Swiss biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics, announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions.